Pharmaceuticals

Meningococcal Vaccines Sector Forecast Shows Robust Momentum, Climbing to $6.58 Billion With 9.1% CAGR

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the meningococcal vaccines market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Meningococcal Vaccines Market by the end of 2030?

The meningococcal vaccines market has observed substantial growth in recent years. It is anticipated to expand from $4.26 billion in 2025 to $4.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The drivers for this past growth include the introduction of meningococcal conjugate vaccines, an increasing frequency of meningitis outbreaks, government-led immunization programs, expanding pediatric vaccination rates, and greater public health funding.

The meningococcal vaccines market is projected to experience substantial expansion in the coming years. This market is forecast to reach $6.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. Factors driving this growth during the forecast period include advances in vaccine technology, the broadening of global immunization efforts, heightened public awareness of meningococcal disease, strategic alliances and joint ventures, and the expansion of vaccination programs targeting adolescents and young adults. Key trends expected over the forecast horizon encompass the enlargement of pediatric vaccination schemes, the creation of comprehensive broad-spectrum meningococcal vaccines, a rise in governmental immunization endeavors, growing understanding of meningococcal disease prevention, and the proliferation of vaccination campaigns in educational institutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Drivers Are Shaping Future Opportunities In The Meningococcal Vaccines Market?

Increased healthcare spending is anticipated to propel the meningococcal vaccine market forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The substantial cost of newer vaccine generations, when compared to their predecessors, is a key consideration in debates over whether their benefits justify their price. Evaluating the comprehensive social and economic benefits of vaccination is becoming an increasingly significant area of inquiry in vaccination valuation literature. For instance, in April 2025, an article by the American Medical Association, a US-based professional association for physicians and medical students, revealed that Health spending in the U.S. rose by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. This growth rate surpassed the 4.6% increase recorded in 2022. Thus, the escalating healthcare spending is driving the expansion of the meningococcal vaccine market.

Which Segments Are Gaining Traction In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

What Upcoming Trends Are Likely To Define The Future Path Of The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are developing novel vaccines for the prevention of serogroups to increase their market profitability. Meningococcal vaccines are designed as preventive measures to protect individuals against infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a pharmaceutical company based in the US, received approval from FDA for its vaccine, PENBRAYA. PENBRAYA, providing extensive serogroup coverage, stands as the most comprehensive U.S.-approved meningococcal vaccine, safeguarding against groups A, B, C, W, and Y. The FDA approval is supported by robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. Pfizer’s announcement in September 2022 had previously revealed positive outcomes from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines regarding safety, tolerability, and immunogenicity.

Who Are The Major Companies Operating In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Meningococcal Vaccines Market?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Meningococcal Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795